Cargando…
HDAC8-Selective Inhibition by PCI-34051 Enhances the Anticancer Effects of ACY-241 in Ovarian Cancer Cells
HDAC6 is overexpressed in ovarian cancer and is known to be correlated with tumorigenesis. Accordingly, ACY-241, a selective HDAC6 inhibitor, is currently under clinical trial and has been tested in combination with various drugs. HDAC8, another member of the HDAC family, has recently gained attenti...
Autores principales: | Kim, Ji Yoon, Han, Seung Yoon, Yoo, Jung, Kim, Go Woon, Jeon, Yu Hyun, Lee, Sang Wu, Park, Jongsun, Kwon, So Hee |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9369251/ https://www.ncbi.nlm.nih.gov/pubmed/35955780 http://dx.doi.org/10.3390/ijms23158645 |
Ejemplares similares
-
Combination of ACY-241 and JQ1 Synergistically Suppresses Metastasis of HNSCC via Regulation of MMP-2 and MMP-9
por: Cho, Ha Young, et al.
Publicado: (2020) -
Selective HDAC inhibition by ACY-241 enhances the activity of paclitaxel in solid tumor models
por: Huang, Pengyu, et al.
Publicado: (2016) -
Enhancement of pomalidomide anti-tumor response with ACY-241, a selective HDAC6 inhibitor
por: North, Brian J., et al.
Publicado: (2017) -
Pathological Role of HDAC8: Cancer and Beyond
por: Kim, Ji Yoon, et al.
Publicado: (2022) -
HDAC8 Deacetylates HIF-1α and Enhances Its Protein Stability to Promote Tumor Growth and Migration in Melanoma
por: Kim, Ji Yoon, et al.
Publicado: (2023)